To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

NCT00294723 on ClinicalTrials.gov · last registry update 2017-03-07

Stopped early, having planned 746 participants. The sponsor logged completion for November 2008. Primary outcome, as filed: Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 746
Started: 2006-02
Primary completion: 2008-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.